(Total Views: 722)
Posted On: 01/16/2018 12:31:52 PM
Post# of 102
CATALYSTS:
1) PEDIATRIC MS(RPI-78M), AMN, MG, ALS
* ORPHAN DRUG STATUS
https://finance.yahoo.com/news/nutra-pharmas-...00069.html
* FDA Trials Phase II coming
* Addresses multiple health conditions
www.receptopharm.com/drug_development
* RPI-78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy AMN).Other neurological disorders that may be served by RPI-78M include Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS)
* Collaboration: University of Maryland,production of RPI-78M for the planned upcoming clinical trials in Pediatric Multiple Sclerosis
https://finance.yahoo.com/news/nutra-pharma-a...00318.html
1) PEDIATRIC MS(RPI-78M), AMN, MG, ALS
* ORPHAN DRUG STATUS
https://finance.yahoo.com/news/nutra-pharmas-...00069.html
* FDA Trials Phase II coming
* Addresses multiple health conditions
www.receptopharm.com/drug_development
* RPI-78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy AMN).Other neurological disorders that may be served by RPI-78M include Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS)
* Collaboration: University of Maryland,production of RPI-78M for the planned upcoming clinical trials in Pediatric Multiple Sclerosis
https://finance.yahoo.com/news/nutra-pharma-a...00318.html
(0)
(0)Scroll down for more posts ▼
